{"id":"hrze-plus-alpe625","_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"AlpE625 is designed to work synergistically with standard tuberculosis antibiotics in the HRZE regimen. The compound acts as an adjuvant to potentiate the activity of existing TB drugs, potentially allowing for shorter treatment duration or improved efficacy against drug-resistant strains.","oneSentence":"Combines standard HRZE tuberculosis therapy with AlpE625, an adjuvant that enhances antibiotic activity against Mycobacterium tuberculosis."},"_scrapedAt":"2026-03-28T03:10:52.485Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123915,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"bedaquiline","brand":"Sirturo","company":"Janssen","rationale":"Novel TB drug for drug-resistant tuberculosis treatment"},{"name":"pretomanid","brand":"Pretomanid","company":"TB Alliance","rationale":"New antibiotic for drug-resistant TB in combination regimens"},{"name":"delamanid","brand":"Deltyba","company":"Otsuka","rationale":"Novel TB treatment for multidrug-resistant tuberculosis"}],"description":"HRZE plus AlpE625 is an investigational combination therapy developed by BioVersys AG for the treatment of tuberculosis. It combines the standard four-drug HRZE regimen (isoniazid, rifampicin, pyrazinamide, ethambutol) with AlpE625, a novel adjuvant compound designed to enhance antibiotic efficacy against Mycobacterium tuberculosis.","indications":{"approved":[{"status":"investigational","condition":"Tuberculosis","patientPopulation":"Adult patients with drug-susceptible tuberculosis"}]},"trialDetails":[{"nctId":"NCT07350174","phase":"PHASE2","title":"Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis","status":"NOT_YET_RECRUITING","sponsor":"BioVersys AG","startDate":"2026-03-30","conditions":"Tuberculosis Meningitis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"HRZE plus AlpE625","genericName":"HRZE plus AlpE625","companyName":"BioVersys AG","companyId":"bioversys-ag","firstApprovalDate":"","aiSummary":"HRZE is a treatment for Tuberculosis Meningitis, and it is being studied in combination with AlpE625 (also known as Alpibectir) in a Phase 2a trial to evaluate its pharmacokinetics and safety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}